Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis.
MAB-T88 is a human monoclonal IgM antibody directed at the lipopolysaccharide of gram-negative bacteria. A protocol was designed to identify a group of septic patients with a very high likelihood of gram-negative bacteremia. All 6 patients entered in the protocol had a gram-negative source, and 4 of 6 had gram-negative bacteremia. In this patient population, MAB-T88 was shown to be safe with an effective half-life of 19.1 hours.
Daifuku
R
R
Cetus Corporation, Emeryville, CA.
Panacek
E A
EA
Haenftling
K
K
Swenson
W K
WK
Prescott
A W
AW
Johnson
J L
JL
D000368:Aged; D000907:Antibodies, Bacterial / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000628:therapy*; D006207:Half-Life; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012475:Salmonella / Q000276:immunology; D018805:Sepsis / Q000628:therapy; D016896:Treatment Outcome
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D008070:Lipopolysaccharides